Global collaboration highlights statins’ potential beyond cholesterol control.
A groundbreaking international study led by the University of Sharjah and the Burjeel Cancer Institute has found that statins may significantly improve survival in patients with certain blood cancers. The study, led by Dr. Ahmad Abuhelwa, analyzed data from 1,467 patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) undergoing modern targeted therapy. Results showed patients on statins had a 61% lower cancer-related death risk, 38% lower overall mortality, and 26% reduced disease progression.
“This is the first systematic evaluation of the link between statin use and survival outcomes in patients with CLL or SLL,” said Dr. Abuhelwa.
Dr. Karem Alzoubi, Dean of Pharmacy, praised the study as a reflection of “dedication to producing impactful scientific studies.”
Prof. Humaid Al Shamsi added, “This study raises an exciting possibility—that a well-known and widely used medication like statins could enhance treatment outcomes.”